EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.

Poeppel, Thorsten D; Handkiewicz-Junak, Daria; Andreeff, Michael; Becherer, Alexander; Bockisch, Andreas; Fricke, Eva; Geworski, Lilli; Heinzel, Alexander; Krause, Bernd J; Krause, Thomas Michael; Mitterhauser, Markus; Sonnenschein, Wilfried; Bodei, Lisa; Delgado-Bolton, Roberto C; Gabriel, Michael (2018). EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. European journal of nuclear medicine and molecular imaging, 45(5), pp. 824-845. Springer 10.1007/s00259-017-3900-4

[img] Text
EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer.pdf - Published Version
Restricted to registered users only until 1 June 2022.
Available under License Publisher holds Copyright.

Download (586kB) | Request a copy

Radium Ra-223 dichloride (radium-223, Xofigo®) is a targeted alpha therapy approved for the treatment of castration-resistant prostate cancer (CRPC) with symptomatic bone metastases and no known visceral metastatic disease. Radium-223 is the first targeted alpha therapy in this indication providing a new treatment option, with evidence of a significant survival benefit, both in overall survival and in the time to the first symptomatic skeletal-related event. The skeleton is the most common metastatic site in patients with advanced prostate cancer. Bone metastases are a clinically significant cause of morbidity and mortality, often resulting in bone pain, pathologic fracture, or spinal cord compression necessitating treatment. Radium-223 is selectively accumulated in the bone, specifically in areas of high bone turnover, by forming complexes with the mineral hydroxyapatite (the inorganic matrix of the bone). The alpha radiation generated during the radioactive decay of radium-223 produces a palliative anti-tumour effect on the bone metastases. The purpose of this guideline is to assist nuclear medicine specialists in evaluating patients who might be candidates for treatment using radium-223, planning and performing this treatment, understanding and evaluating its consequences, and improving patient management during therapy and follow-up.

Item Type:

Journal Article (Review Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Pavillon 52 > Forschungsgruppe Klinische Radiopharmazie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > Forschungsbereich Pavillon 52 > Forschungsgruppe Klinische Radiopharmazie

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Krause, Thomas Michael

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1619-7070

Publisher:

Springer

Language:

English

Submitter:

Franziska Nicoletti

Date Deposited:

30 Jan 2018 10:29

Last Modified:

23 Oct 2019 13:39

Publisher DOI:

10.1007/s00259-017-3900-4

PubMed ID:

29234845

Uncontrolled Keywords:

Alpha emitters Bone metastases Prostate cancer Radionuclide therapy Radium-223 Survival benefit

BORIS DOI:

10.7892/boris.109342

URI:

https://boris.unibe.ch/id/eprint/109342

Actions (login required)

Edit item Edit item
Provide Feedback